摘要
目的探讨联用鼠神经生长因子与依达拉奉治疗脑出血患者的临床效果及安全性。方法选取2019年2月至2020年2月辽阳市第二人民医院收治的124例脑出血患者作为研究对象,按治疗方式不同将其分为单一组(给予依达拉奉治疗)和联合组(在单一组的基础上联合鼠神经生长因子治疗),每组62例。比较两组治疗前、治疗半个月后的美国国立卫生研究院卒中量表(NIHSS)、日常生活活动能力量表(ADL)评分以及S100B蛋白、血清神经元特异性烯醇化酶(NSE)、髓鞘碱性蛋白(MBP)水平,并比较两组治疗后不良反应发生率。结果治疗后,联合组NIHSS评分低于单一组,而ADL评分高于单一组,差异有统计学意义(P<0.05);治疗后联合组S100B蛋白、NSE、MBP水平低于单一组,差异有统计学意义(P<0.05);联合组不良反应发生率为6.45%,低于单一组12.90%,但差异无统计学意义(P>0.05)。结论给予脑出血患者鼠神经生长因子与依达拉奉联合治疗,可有效修复患者的受损的神经,提升日常生活能力,且不良反应小,安全性好。
Objective To explore the clinical effects and safety of combined use of mouse nerve growth factor and edaravone in the treatment of patients with cerebral hemorrhage. Methods A total of 124 patients with cerebral hemorrhage admitted to the Second People’s Hospital of Liaoyang City from February 2019 to February 2020 were selected as the research objects. According to different treatment methods, they were divided into a single group(treated with Edaravone) and a combined group(treated with mouse nerve growth factor on the basis of single group), with 62 cases in each group. The NIHSS, ADL scores, S100 B protein, NSE and MBP levels were compared before and half a month after treatment, and the incidence of adverse reactions was compared between the 2 groups. Results After treatment, the NIHSS score of the combined group was lower than that of the single group, while the ADL score was higher than that of the single group, the difference was statistically significant(P<0.05);the S100 B protein, NSE, MBP levels of the combined group were lower than those of the single group, the difference was statistically significant(P<0.05);the incidence of adverse reactions in the combined group was 6.45%, lower than that in the single group(12.90%), but there was no significant difference in the results(P>0.05). Conclusion The combined treatment of mouse nerve growth factor and edaravone in patients with cerebral hemorrhage can effectively repair the damaged nerves and improve the ability of daily life, with little adverse reactions and good safety.
作者
于洋
YU Yang(The Second Department of Neurology,the Second People's Hospital of Liaoyang City,Liaoyang 111010,China)
出处
《中国药物经济学》
2021年第8期100-102,106,共4页
China Journal of Pharmaceutical Economics
关键词
鼠神经生长因子
依达拉奉
脑出血
安全性
不良反应
Mouse nerve growth factor
Edaravone
Intracerebral hemorrhage
Safety
Adverse reactions